Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

90

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

90 results for “Laboratory tests”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH

ClinicalTrials.gov study NCT05421949. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Re-Purposing the Ordering of Routine Laboratory Tests in Hospitals in British Columbia

ClinicalTrials.gov study NCT06359587. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

ClinicalTrials.gov study NCT03551743. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Validation of Laboratory Test for Predicting Bone Tissue Regeneration

ClinicalTrials.gov study NCT01362413. IPD Sharing: Not stated. Countries: 1. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)

ClinicalTrials.gov study NCT05845593. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

User Site Testing Study to Evaluate Usability of the Q300™ Device Under "Real-life Conditions" in a Reproductive Laboratory Environment Use

ClinicalTrials.gov study NCT06232720. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Evidence-based Laboratory Test Order Sets in Primary Care

ClinicalTrials.gov study NCT02950142. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
zenodo28/100

Geomechanical characterisation of discontinuous greywacke from the Wellington region based on laboratory testing: Dataset

<p>Greywacke rock masses are the most prominent bedrock type across New Zealand, forming approximately 20 % of the country. This paper reviews the publicly available laboratory testing data on the geomechanical properties of greywacke from the Wellington region and compares the results with two recent studies. This includes compilations of density, unconfined compressive strengths, tensile strengths, Poisson&rsquo;s ratio, Young&rsquo;s Modulus, and m<sub>i</sub> factor. This paper also presents the first published geomechanical data from a cataclasite zone in the greywacke of the Wellington region. The overall results presented in this paper highlight the influence of both weathering and discontinuities on the geomechanical properties derived from the testing of core samples. The results are discussed in the context of sampling bias, scale effects and recent developments in the geomechanical characterisation of discontinuous rock. Two different approaches for characterising the rock mass geomechanical properties of greywacke at the project-scale are presented. The first approach uses the GSI as the main parameter to capture the change in rock mass character with depth while the UCS remains constant. The second approach uses the UCS as the main parameter to capture the change in rock mass character with depth while the GSI value remains constant.</p>

opencc-by-4.0Nov 2020View details →
zenodo28/100

Supplementary material 2 from: Lang A, Dolek M, Lee MS, Freese-Hager A, Otto M (2020) Selection of non-target Lepidoptera species to test Bt maize effects in the laboratory: which species and how to breed them? BioRisk 15: 45-65. https://doi.org/10.3897/biorisk.15.59823

Review breeding information

opencc-zeroJan 2021View details →
zenodo28/100

Supplementary material 1 from: Lang A, Dolek M, Lee MS, Freese-Hager A, Otto M (2020) Selection of non-target Lepidoptera species to test Bt maize effects in the laboratory: which species and how to breed them? BioRisk 15: 45-65. https://doi.org/10.3897/biorisk.15.59823

Reference list: breeding and rearing Lepidoptera

opencc-zeroJan 2021View details →
zenodo28/100

Supplementary Data for Manuscript "Examining the mid to long-term variability in saturated hydraulic conductivity of sandy soils and its influencing factors under constant head test in the laboratory"

Open the record for dataset details and reuse information.

opencc-by-4.0Jan 2024View details →
zenodo28/100

Mitigating Rainfall Induced Soil Erosion through Bio-approach: From Laboratory Test to Field Trail

Open the record for dataset details and reuse information.

opencc-by-4.0Apr 2024View details →
zenodo28/100

Supplementary material 1 from: Hall RM, Urban B, Skalova H, Moravcová L, Sölter U, Starfinger U, Kazinczi G, van Valkenburg J, Fenesi A, Konstantinovic B, Uludag A, Lommen S, Karrer G (2021) Seed viability of common ragweed (Ambrosia artemisiifolia L.) is affected by seed origin and age, but also by testing method and laboratory. NeoBiota 70: 193-221. https://doi.org/10.3897/neobiota.70.66915

Supporting tables and figures

opencc-zeroDec 2021View details →
zenodo28/100

Figure 2 in Compatibility of entomopathogenic nematodes with plant extracts and post-exposure virulence test under laboratory condition

Figure 2. Percentage survival of the individual EPN species at different concentrations of aqueous and ethanol extracts of A. amatymbica and E. elephantina. Vertical bars illustrate the standard error of the mean (n = 3).

opencc-by-4.0May 2021View details →
dryad28/100

Supplemental table from: CLIA laboratory testing for Facioscapulohumeral Dystrophy (FSHD): a retrospective analysis

<p><span><span><span><span><span><span><span><span><span><span><span><b>Objective:</b> To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods:</b> All FSHD tests performed in the diagnostic laboratory January 2015-July 2019 were retrospectively reviewed. Testing was by restriction enzyme digestion and Southern blot analysis with sequencing of <i>SMCHD1,</i> if indicated. Cases were classified as FSHD1 (4q35 EcoRI size ≤40kb; 1-10 D4Z4 repeats), FSHD2 (permissive 4q35A allele, D4Z4 hypomethylation, and  pathogenic <i>SMCHD1</i> variant), or non-FSHD1,2. We also noted cases with borderline EcoRI fragment size (41-43kb; 11 D4Z4 repeats), cases that meet criteria for both FSHD1 and FSHD2, somatic mosaicism, and cases with hybrid alleles that add complexity to test interpretation. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results:</b> Of the 1594 FSHD tests included in the analysis, 703 (44.1%) were diagnosed with FSHD. Among these positive tests, 664 (94.5%) met criteria for FSHD1 and 39 (5.5%) met criteria for FSHD2. Of all 1594 cases, 20 (1.3%) had a 4q35 allele of borderline size, 23 (1.5%) were somatic mosaics, and 328 (20.9%) had undergone translocation events. Considering only cases with at least one 4q35A allele, D4Z4 repeat number differed significantly among groups: FSHD1 cases median of 6.0 (IQR: 4-7) repeats, FSHD2 cases 15.0 (IQR: 12-22) repeats, and non-FSHD1,2 cases 28.0 (IQR: 19-40) repeats. </span></span></span></span></span></span></span></span></span></span></span></p> <p><strong>Conclusion: </strong>FSHD1 accounts for 94.5% of genetically confirmed cases of FSHD. The data show a continuum of D4Z4 repeat numbers with FSHD1 samples having the fewest, FSHD2 an intermediate number, and non-FSHD1,2 the most.</p>

opencc-zeroOct 2021View details →
ClinicalTrials.gov28/100

Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers

ClinicalTrials.gov study NCT04445415. IPD Sharing: Not stated. Countries: 0. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

ClinicalTrials.gov study NCT03551730. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

The Impact of Charge Displays on Inpatient Laboratory Test Ordering

ClinicalTrials.gov study NCT02355496. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing t

ClinicalTrials.gov study NCT06578754. IPD Sharing: NO. Countries: 0. Publications: 5.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Effect of Norms on Laboratory and Imaging Testing (ENLITen)

ClinicalTrials.gov study NCT02330289. IPD Sharing: Not stated. Countries: 0. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record